This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bertolet, B. D. Articles by Pepine, C. J. Search for Related Content PubMed PubMed Citation Articles by Bertolet, B. D. Articles by Pepine, C. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

(Circulation. 1996;94:1212-1215.)
© 1996 American Heart Association, Inc.

Articles

Effects of A₁ Adenosine Receptor Agonism Using N⁶-Cyclohexyl-2'-O-Methyladenosine in Patients With Left Ventricular Dysfunction

Barry D. Bertolet, MD; Inder S. Anand, MD; Robert J. Bryg, MD; Pramod K. Mohanty, MD; Kanu Chatterjee, MD; Jay N. Cohn, MD; Nardev S. Khurmi, MD; Carl J. Pepine, MD

the Department of Medicine, Division of Cardiology, University of Florida Health Sciences Center, Gainesville.

Correspondence to Barry D. Bertolet, MD, Division of Cardiology, PO Box 100277, JHMHC, University of Florida, Gainesville, FL 32610-0277.

Background The role of adenosine as a neuromodulator in heart failure was studied with the use of a selective adenosine A₁ receptor agonist, N⁶-cyclohexyl-2'-O-methyladenosine (SDZ-WAG 994).

Methods and Results Fifty patients with heart failure symptoms and moderate left ventricular systolic dysfunction had a balloon flotation catheter inserted. Patients received placebo or a single oral dose of either 1, 2, or 5 mg SDZ-WAG 994. After baseline measurements were obtained, hemodynamic and electrophysiological recordings were repeated at 30-minute intervals for the next 4 hours, then every 6 hours for the next 24 hours. Blood samples for norepinephrine, epinephrine, aldosterone, atrial natriuretic peptide, and plasma renin activity were drawn at baseline and 2 hours after drug administration. A₁ adenosine receptor agonism produced no important effects on systemic, right atrial, pulmonary artery, or pulmonary capillary wedge pressures; cardiac index; respiratory rate; or heart rate. The PR interval (a reflection of A₁ receptor–mediated activity) increased significantly in a stepwise fashion. At the 5-mg dose of SDZ-WAG 994, significant increases in atrial natriuretic peptide (216±137 to 407±146 pg/mL) and norepinephrine (477±243 to 618±237 pg/mL) levels were noted.

Conclusions A₁ adenosine receptor agonism with SDZ-WAG 994 resulted in no significant hemodynamic changes at rest in this subset of patients with left ventricular dysfunction. An increase in the PR interval and atrial natriuretic peptide level, consistent with adenosine A₁ receptor–mediated activity, was observed. In addition, an increase in the norepinephrine level was observed, suggesting a role for adenosine as a peripheral nervous system neuromodulator.

Key Words: adenosine • receptors • atrial natriuretic factor • norepinephrine

This article has been cited by other articles:

				F Franceschi, J-C Deharo, R Giorgi, Y By, C Monserrat, J Condo, Z Ibrahim, A Saadjian, and R Guieu Peripheral plasma adenosine release in patients with chronic heart failure Heart, April 1, 2009; 95(8): 651 - 655. [Abstract] [Full Text] [PDF]

				V. Vallon, C. Miracle, and S. Thomson Adenosine and kidney function: Potential implications in patients with heart failure Eur J Heart Fail, February 1, 2008; 10(2): 176 - 187. [Abstract] [Full Text] [PDF]